Evaluating Next-Generation BTK Inhibitors

This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the US, and data that were presented in abstract form. These data should be considered preliminary until published in a peer-reviewed journal

BTK Overview

First-Generation BTK Inhibitor Ibrutinib

Second-Generation BTK Inhibitor Acalabrutinib

Acalabrutinib and Ibrutinib Dosing

Approved Indications Ibrutinib

Ibrutinib in Relapsed CLL Phase 1 Data

Efficacy of Ibrutinib in Other Disease States

Ibrutinib vs Ofatumumab in Previously Treated CLL

Ibrutinib AEs

Challenges With Ibrutinib Use

Risk Factors for Major Hemorrhage in Patients Treated with Ibrutinib

Management of Atrial Fibrillation

Managing Infections

Mechanisms of Resistance

Acalabrutinib Pharmacodynamics

Acalabrutinib in Relapsed CLL Results

Acalabrutinib in Relapsed CLL AEs

Acalabrutinib in Relapsed/Refractory MCL

Acalabrutinib in Relapsed/Refractory MCL AEs

Management of Acalabrutinib AEs

Acalabrutinib or Ibrutinib?

Guideline Recommendations for Ibrutinib and Acalabrutinib

Second-Generation BTK Inhibitor Pipeline and Other Novel Combinations

Other Novel Combination Trials

Genomic-Driven Ibrutinib Treatment in MCL

Concluding Remarks

Abbreviations

Abbreviations (cont)

Abbreviations (cont)